About US
Contact us
-
CSL Behring receives FDA approval to treat haemophilia ACSL Behring has received approval from the US Food and Drug Administration (FDA) for the use of its recombinant factor VIII single-chain therapy, Afstyla, as a treatment for haemophilia A. Hemophilia2016/6/1
-
Inserm researchers develop new drugs to treat skin cancerA team from French National Institute of Health and Medical Research Inserm led by Stéphane Rocchi has synthesised and developed new drugs to treat melanoma, a highly malignant form of skin cancer. O2016/5/31
-
Samsung Bioepis secures EC approval to market RA biosimilar Flixabi in EUSamsung Bioepis, a joint venture between Samsung BioLogics and Biogen, has secured approval from the European Commission (EC) to market rheumatoid arthritis (RA) biosimilar, Flixabi, in the European U2016/5/31
-
M&As this week: Biodel, Dirui Industrial and THERAMetricsBiodelhas entered an agreement to merge with Albireo Pharma, Inc. to form a combined company whereby the former's shareholders will own 33% and the latter's will own the rest. The new company will fo2016/5/30
-
US FDA grants Fast Track Designation to Novavax’s RSV F VaccineThe US Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax's respiratory syncytial virus (RSV) F-Protein nanoparticle vaccine candidate (RSV F Vaccine) that can be used to2016/5/30
-
US FDA's EMDAC recommends approval of Sanofi’s NDA to treat type II diabetesThe US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has recommended the approval for French-based Sanofi's New Drug Application (NDA) to treat typ2016/5/27
-
UK CRT and Pangaea Biotech to develop new drugs to treat cancerUK's Cancer Research Technology (CRT) has signed a licence agreement with Spanish company Pangaea Biotech, to develop p21-activated kinase (PAK) inhibitor drugs to treat cancer. Scientists at CRT's D2016/5/27
-
Novartis establishes new global clinical programme of Entresto and heart failureSwiss pharmaceutical company Novartis has established a global clinical programme, Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy), to address the heart failure disea2016/5/26
-
Deals this week: Trianni, ANI Pharma, Merus LabsTrianni and Evotec AGhave entered a co-development agreement to develop Evotec's existing drug discovery platforms, as well as new projects. The agreement enables Evotec to gain access to the Trianni2016/5/26
-
CGT and Aberdeen University establish new company for diabetes treatmentUK-based cell and gene therapy industry Cell and Gene Therapy Catapult (CGT), along with the University of Aberdeen, has announced the establishment of new company Islexa. Islexa is set-up to develop2016/5/25